The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of “Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2026 |
Kazutaka Nakamura, Kazuhiko Yoshida, Yuki Kobari, Yuki Nemoto, Hiroki Ishihara, Hironori Fukuda, Junpei Iizuka, Hiroaki Shimmura, Hiroshi Kobayashi, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi. Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma, International Urology and Nephrology. 2026; https://doi.org/10.1007/s11255-026-05174-5 |
|
2 |
2025 |
Ilya Tsimafeyeu, Future perspectives: targeting fibroblast growth factor receptor 1 to enhance the efficacy of immunotherapy, Exploration of Targeted Anti-tumor Therapy. 2025; 6: 1002327. https://doi.org/10.37349/etat.2025.1002327 |